Channel Therapeutics announces 10-for-1 reverse split ahead of NYSE American uplisting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Reverse Stock Split Announcement: Channel Therapeutics will execute a 10-for-1 reverse stock split on July 1, 2025, to comply with NYSE American listing requirements ahead of a merger and capital raise.
Company Name Change: Following the reverse split, the company will be renamed Pelthos Therapeutics and will start trading under this new name on July 2, 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
